Viriom Launches Reproductive Toxicity Studies for Elpida® (Elsulfavirine) Once Weekly Oral Formulation

SAN DIEGO, Dec. 3, 2019

/PRNewswire/ -- Viriom Inc (Viriom) announces launching Segment I and Segment

II reproductive toxicity studies of Elpida® (elsulfavirine) HIV-1 therapy,

supported by preclinical services of the Division of AIDS at the National

Institute of Allergy and Infectious Diseases, part of the National Institutes

of Health.

These preclinical studies are

critical for the Food and Drug Administration (FDA) drug approval process and

for bringing Elpida® once weekly oral formulation to the market in the United

States. The studies are executed by SRI International (www.sri.com) and Covance

(www.covance.com). 

About Elpida® (elsulfavirine):

Elsulfavirine is an investigational new drug that is being studied in once

daily and once weekly oral long-acting formulations to treat HIV. Elsulfavirine

belongs to a group of HIV drugs called non-nucleoside reverse transcriptase

inhibitors (NNRTIs). NNRTIs attach to and block an HIV enzyme called reverse

transcriptase. Studies have shown that elsulfavirine appears effective for

treating HIV in people who have not previously taken HIV medicines.

Elsulfavirine may also be effective against certain strains of HIV that can no

longer be controlled by Food and Drug Administration (FDA)-approved NNRTIs.

Viriom is also developing a long-acting injectable formulation of

investigational new drug VM1500A-LAI to prevent HIV.

About Viriom: Viriom (San

Diego, CA) focuses on the treatment, prophylaxis, and eradication of infectious

diseases globally. Viriom is developing and commercializing the most innovative

and affordable solutions to radically expand global access to the best

antiviral treatments. Viriom's broad, proprietary, and partnered pipeline

covers therapeutic, prophylactic, and curative medicines for HIV and viral

hepatitis. Learn more at www.viriom.com.

Media Contact: Iain Dukes CEO, Viriom Inc +1 (212) 739-6444

idukes@viriom.com

SOURCE Viriom

https://www.prnewswire.com/news-releases/viriom-launches-reproductive-toxicity-studies-for-elpida-elsulfavirine-once-weekly-oral-formulation-300967876.html